Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis

Table 1 Summary of trials of GMCAP therapy using Adacolumn for patients with active UC

Authors (yr)	Indications forGMCAP	n	Apheresisprotocol	Adverse effects(% of patients)	Efficacy (%)
Shimoyama et al[9]	Refractory to	53	Standard1	9%	Remission: 21%
(2001)	conventional drugs				Improvement: 37%
Tomomasa et al[10] (2003)	Steroid-refractory children	12	1 session/wk for 5-10 wk	9%	Improvement: 67%
Hanai et al[11]	Steroid-refractory	31	10 or 11 sessions	18%	Remission:
(2003)	Steroid-naive	8	over 11 wk		Steroid-refractory 81%
					Steroid-naive 88%
					Improvement:
					Steroid-refractory 6%
					Steroid-naive 12%
Suzuki et al[12]	Steroid-naive	20	2 sessions/wk	10%	Remission: 85%
(2004)			for 3-5 wk
Naganuma et al[13]	Steroid-refractory	44	Standard1	5%	Remission: 55%
(2004)	Steroid-dependent				Improvement: 20%
Hanai[14]	Steroid-dependent	46	11 sessions over 10 wk	22%	Remission: 83%
(2004)2
Yamamoto et al[15]	Mild-to-moderate	30	Standard1	27%	Remission: 70%
(2004)	active distal disease				Improvement: 17%
Domenech et al[16]	Steroid-dependent	14	Standard1	15%	Remission: 62%
(2004)3					Improvement: 14%
Kanke et al[17]	Mild-to-severe disease	60	10 sessions over 12 wk4	18%	Remission: 23%
(2004)					Improvement: 60%
Kim et al[18] (2005)	Refractory to conventional drugs	27	Standard1	11%	Improvement: 70%

GMCAP, granulocyte and monocyte/macrophage adsorptive apheresis; UC, ulcerative colitis.

¹Five apheresis sessions for five consecutive weeks; session time, 60 min; blood flow rate, 30 mL/min.

²This study was a randomized controlled trial comparing efficacy of GMCAP and prednisolone.

³This study also included 12 patients with Crohn’s disease.

⁴One or two sessions per week; session time, 60 or 90 min.